Fasenra gets bad news

Dupixent is coming for severe asthma, October 2018.

 

So what? Dosing schedule is every 2-4 wks with no clinical advantage.

 

Too bad about the no COPD indication, LOL. I hope all you people who were promised a drug to sell for COPD are okay with looking for employment in about 6 months. AZ will ALWAYS hire and fire people at will. Good luck in your job search.

 

Stop your bitching! To bad you were fired for being a bad rep, now you are looking from the outside and know you fu@ked up and lost a good opportunity! Troll somewhere else loser!

 

We are doomed Excellent post

 

AGREE!!!!!!

 

You obviously have no fucking clue of what your talking about. There is a massive clinical advantage! Read up dipshit!

 

My family member is on it, after switching from Xolair. Dosing schedule was great and she was controlled when every month. Now that the schedule is every other, she has had breakthrough exacerbations, I know all drugs aren't for everyone, but I didn't think it would be this ineffective going to every other. Maybe they can dose it every month? Thoughts?

 

The 2 pivotal Fasenra studies were designed to compare the efficacy of the once every month dose and the once every 2 month dose against placebo. The studies were not powered to compare the effectiveness of one dosing regimen over the other.

Still, it’s a mistake by AZ not to consider including the option for a once every month dose in the label as Fasenra’s effectiveness is starting to become an issue.

 

Unfortunately, more bad news for Fasenra (and Nucala).

Dupixent was approved last Friday for treatment of moderate-to-severe asthma with major advantages. It can be administered at home unlike Fasenra which has to be administered in clinic. It’s not restricted to eosinophilic asthma but can be given to patients with oral corticosteroid dependent asthma which broadens its market considerably. And it’s already on formulary for atopic dermatitis a condition in which 3% have moderate to severe asthma.

With these advantages it is expected that for starters Dupixent will grab about a 10% market share from Fasenra.

 

Interesting.
3% have AD and Severe Asthma. That’s huge!
So which of the reps gets credit for this patient (derm or asthma)? Are these patients already on Dupi for AD? Why not? “It’s already on formulary for AD.”
Good luck with the co-promotion.

OCS Dependent broadens market considerably? Really?

It’s great to have your glass is half full approach, but what are you trying to prove by writing on this board? So long as you believe it, that’s what matters.

 

Dupixant has done nothing in my territory. Fasenra is a hell of a drug and if you are not selling it maybe the Nucala rep is better than you.

 

Hopefully you are a troll from GSK. If you’re a rep for Fasenra, don’t troll our other selling teams. I am a rep for Fasenra and have great counterparts in my area.

FYI - You didn’t even spell DUPIXENT correct.

 

Administered at home? Awesome only if HMO's push this for you. You think that is a selling point for allergists? Oh yeah, take $ out of their pocket. They love that.

 

Don’t underestimate the marketing advantage of at home administration over administration in clinic.

As we speak, the MedI clinical and safety team is desperately making the case for at home administration if they can convince the FDA that the worrisome and increasing post-market incidence of allergic reactions and anaphylaxis with Fasenra is not a problem and does not require trained personnel to administer it.

 

KK in Oncology is a sexist bully. He belittles every woman he speaks to and I have not only experienced it personally but have seen him yell at other women who are sales reps and msls. He makes them feel small, irrelevant, and dumb. He has said that “back in the day” he didn’t have women bosses but then everything got politically correct so now he has to listen to their bad ideas. He is an argumentative person and fights with males employees - but he doesn’t insult the men and tell them they are dumb. He only does this with women. And he makes inappropriate comments about the legs of women he sees when he golfs. He is creepy. He makes the work environment very uncomfortable. He is an angry person. He is a BULLY. Oncology leadership knows it and they look the other way because they only care about results. Olivier knows it. Jane know it. Kevin knows it. Gaby knew it. Mike C knows it. Randy knows it. Katy knows it. KK side kick philippe knows it. Philippe is accessory after the fact because he supports KK’s behavior. Managment won’t do anything about it. They just say it’s is “KK being KK” because that’s easier and that KK been around for a long time. Unacceptable. Oncology leadership should be ashamed. With KK there Oncology is not a safe place for women unless you want to be demeaned, feel like your dumb, and that women don’t have a place. KK should not work around women. He is a BULLY. A chauvinist BULLY. A BULLY that doesn’t live the AZ values. If you meet him - stay away.

 

Can’t say I am familiar with KK as I do not work in oncology. Doesn’t sound like you’re a fan of his.